Publicacións (70) Publicacións nas que participase algún/ha investigador/a

filter_list Internal Medicine

2024

  1. Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 1, pp. 23-32

  2. New Vaccines for Chronic Respiratory Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 9, pp. 565-575

  3. Outpatient glucocorticoid use and COVID-19 outcomes: a population-based study

    Inflammopharmacology, Vol. 32, Núm. 4, pp. 2305-2315

  4. Tezepelumab decreases airway epithelial IL-33 and T2-inflammation in response to viral stimulation in patients with asthma

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 79, Núm. 3, pp. 656-666

  5. Triple inhaled therapy in asthma: Beliefs, behaviours and doubts

    Pulmonary Pharmacology and Therapeutics, Vol. 87

2023

  1. A Study of the Prevalence of Asthma in the General Population in Spain

    Open Respiratory Archives, Vol. 5, Núm. 2

  2. Alpha-1 antitrypsin deficiency and Pi*S and Pi*Z SERPINA1 variants are associated with asthma exacerbations

    Pulmonology

  3. Analysis of Differentially Expressed MicroRNAs in Serum and Lung Tissues from Individuals with Severe Asthma Treated with Oral Glucocorticoids

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

  4. Disposition of Work-Related Asthma in a Spanish Asthma Cohort: Comparison of Asthma Severity Between Employed and Retired Workers

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 11, pp. 3407-3413.e1

  5. Exacerbations Among Patients With Asthma Are Largely Dependent on the Presence of Multimorbidity

    Journal of Investigational Allergology and Clinical Immunology, Vol. 33, Núm. 4, pp. 281-288

  6. Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study

    Drugs, Vol. 83, Núm. 12, pp. 1111-1123

  7. Prognostic Usefulness of Basic Analytical Data in Chronic Obstructive Pulmonary Disease Exacerbation

    Open Respiratory Archives, Vol. 5, Núm. 4

  8. Serum exosome inflamma-miRs are surrogate biomarkers for asthma phenotype and severity

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, Núm. 1, pp. 141-155

  9. Treatment Patterns of Monoclonal Antibodies in Patients With Severe Uncontrolled Asthma Treated by Pulmonologists in Spain

    Open Respiratory Archives, Vol. 5, Núm. 3